March 11, 2020 / 12:41 PM / a month ago

BRIEF-Spero Therapeutics Receives FDA Orphan Drug Designation For SPR720

March 11 (Reuters) - Spero Therapeutics Inc:

* SPERO THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SPR720 FOR THE TREATMENT OF NONTUBERCULOUS MYCOBACTERIAL (NTM) INFECTION

* SPERO THERAPEUTICS INC - EXPECTS TO PRESENT FINAL DATA FROM SPR720 PHASE 1 CLINICAL TRIAL AT A MEDICAL CONFERENCE DURING 2020

* SPERO THERAPEUTICS - PLANS TO MEET WITH FDA IN FIRST HALF OF 2020, SUBMIT IND APPLICATION FOR SPR720 TO FDA IN SECOND HALF OF 2020

* SPERO THERAPEUTICS -SUBJECT TO FDA ACCEPTANCE OF SPR720 IND, EXPECTS TO INITIATE DOSE-RANGING PHASE 2A CLINICAL TRIAL EVALUATING SPR720 IN H2 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below